Anti-LRRK2/Dardarin, N-Terminus Antibody (N138/6)

Our Anti-Dardarin/LRRK2, N-terminus mouse monoclonal primary antibody from NeuroMab is produced in-house from hybridoma clone N138/6. It is KO validated, detects human, mouse, and rat Dardarin/LRRK2, N-terminus, and is purified by Protein A chromatography. It is great for use in ICC, WB.



SKU: 75-188

Volume: 100 µL
1-2 business days
Price:
Sale price$319

Product Specific References for Applications and Species

Immunocytochemistry: Mouse
PMID Dilution Publication
25201882not listedCho, H.J., et al. 2014. Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.. The EMBO Journal, 2314-2331.
244640401:200Parisiadou, L., et al. 2014. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.. Nature Neuroscience, 367-376.
Immunohistochemistry: Mouse
PMID Dilution Publication
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
Immunohistochemistry: Rat
PMID Dilution Publication
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
Immunoprecipitation: Human
PMID Dilution Publication
272735691:1000Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
22423108not listedXiong, Y., et al. 2012. ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2.. Journal of Neuroscience, 3877-3886.
Immunoprecipitation: Mouse
PMID Dilution Publication
329190312ulKuwahara, T., et al. 2020. Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation. Neurobiology of Disease, 105081.
272735691:1000Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
2201298510ugGómez-Suaga, P., et al. 2012. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP.. Human Molecular Genetics, 511-525.
220044532.5ugDoggett, E.A., et al. 2012. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson''s disease mutations and LRRK2 pharmacological inhibition.. Journal of Neurochemistry, 37-45.
Western Blot: Human
PMID Dilution Publication
272735691:1000Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
24947832not listedReyniers, L., et al. 2014. Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.. Journal of Neurochemistry, 239-250.
24917786not listedVancraenenbroeck, R., et al. 2014. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.. Frontiers in Molecular Neuroscience, 51.
23916833not listedManzoni, C., et al. 2013. Inhibition of LRRK2 kinase activity stimulates macroautophagy.. Biochimica et Biophysica Acta, 2900-2910.
Western Blot: Mouse
PMID Dilution Publication
37366237not listedLiu, Q., et al. 2023. Regulation of LRRK2 mRNA Stability by ATIC and its Substrate AICAR Through ARE-mediated mRNA Decay in Parkinson's Disease. The EMBO Journal, e113410.
34759048not listedKim, J.W., et al. 2021. Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. eNeuro, .
30592011not listedDe Wit, T., et al. 2019. Inhibition of LRRK2 or casein kinase 1 results in LRRK2 protein destabilization. Molecular Neurobiology, 5273-5286.
28321439not listedXiong, Y., et al. 2017. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. eNeuro, .
281039011:1000Berwick, D.C., et al. 2017. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.. Molecular Neurodegeneration, 9.
273786961:1000Ma, B., et al. 2016. LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways. Human Molecular Genetics, 3515-3523.
272735691:1000Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
244640401:1000Parisiadou, L., et al. 2014. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.. Nature Neuroscience, 367-376.
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
23125283not listedCho, H.J., et al. 2013. MicroRNA-205 regulates the expression of Parkinson''s disease-related leucine-rich repeat kinase 2 protein.. Human Molecular Genetics, 608-622.
22899650not listedBerwick, D.C., et al. 2012. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6.. Human Molecular Genetics, 4966-4979.
20016100not listedAndres-Mateos, E., et al. 2009. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).. Journal of Neuroscience, 15846-15850.
Western Blot: Rat
PMID Dilution Publication
235607501:1000Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Bulk Order Anti-LRRK2/Dardarin, N-Terminus Antibody

Related Products

Recently Viewed